Sight Sciences Earnings Call Transcripts
Fiscal Year 2026
-
The conference highlighted strong momentum for interventional glaucoma and dry eye, with growing adoption driven by early adopters, reimbursement expansion, and cross-segment synergies. Product innovation and manufacturing diversification support long-term growth, while prudent financial guidance and disciplined investment underpin the outlook.
Fiscal Year 2025
-
Q4 2025 saw 7% revenue growth, strong gross margins, and reduced operating expenses, with both interventional glaucoma and dry eye segments contributing. 2026 guidance projects 6–14% revenue growth, driven by commercial investments and expanding reimbursement.
-
Significant progress was made with TearCare's reimbursement and commercialization, supported by strong clinical and economic data. The surgical glaucoma segment gained market share, and disciplined financial management positions the business for growth in both core areas.
-
Q3 revenue reached $19.9M, led by surgical glaucoma growth, while dry eye revenue declined as focus shifted to reimbursed market access. Full-year 2025 revenue guidance was raised to $76M–$78M, and operating expenses were reduced. Medicare fee schedules for TearCare and new executive appointments position both segments for growth in 2026.
-
Glaucoma and dry eye markets are evolving toward more interventional, less invasive treatments, with strong clinical evidence and innovation driving adoption. Despite reimbursement headwinds, growth is expected to resume, and payer feedback on new dry eye procedures is positive, targeting policy wins in 2025.
-
Second quarter revenue reached $19.6 million, driven by strong surgical glaucoma performance and positive OMNI Edge adoption, despite year-over-year declines due to Medicare LCD headwinds. Full year 2025 revenue guidance was raised, and robust clinical data supports ongoing efforts for TearCare reimbursement.
-
Surgical glaucoma revenue outperformed expectations despite new MIGS restrictions, with Omni and Scion gaining share as the market adapts. LCD headwinds are expected to subside by Q1 2026, supporting future growth. TearCare is poised for payer coverage, targeting a large, underpenetrated dry eye market.
-
Q1 2025 revenue declined 9% year-over-year to $17.5 million, with surgical glaucoma down 6% and dry eye down due to pricing changes. Full-year revenue guidance of $70–$75 million was reaffirmed, and adjusted operating expense guidance was lowered to $101–$105 million. Tariff impacts and Medicare restrictions remain key risks.
-
Revenue guidance for 2024 is $70–$75 million, with sequential improvement expected and strong gross margins, though tariffs may impact later quarters. MIGS market headwinds are offset by competitive positioning and a growing interventional mindset. TearCare is poised for growth with anticipated reimbursement wins in 2025.
-
Recent Medicare LCDs confirmed coverage for key glaucoma procedures but restricted stacking, impacting about 15% of the MIGS market. OMNI is positioned as a comprehensive solution, while TearCare is targeting payer coverage in 2025 with a strong clinical and economic case.
Fiscal Year 2024
-
Q4 2024 revenue grew 2% year-over-year, led by surgical glaucoma, while dry eye revenue declined as focus shifted to reimbursement. 2025 guidance reflects headwinds from Medicare LCD changes and tariffs, with OMNI Edge launch and TearCare reimbursement wins as key catalysts.
-
Glaucoma procedural adoption is growing, with OMNI positioned as a comprehensive solution amid reimbursement changes. Q3 revenues were impacted by LCD uncertainty, but efforts are focused on standalone and dry eye markets. TearCare is poised for growth pending reimbursement wins, and a $34M litigation verdict is pending final ruling.
-
Q3 2024 revenue grew 1% year-over-year to $20.2 million, with surgical glaucoma up 1% and dry eye down 4% but ahead of expectations. LCD changes created short-term headwinds, but coverage clarity and organizational improvements are expected to drive growth in 2025.
-
Q2 saw double-digit sequential growth and strong gross margins, with a narrowed guide due to a TearCare price hike. LCD uncertainty has cleared, and new reimbursement and device-intensive status could drive growth in 2025. TearCare's market access strategy targets a large unmet need, with payer engagement ongoing.
-
Q2 2024 revenue grew 11% sequentially to $21.4M, with surgical glaucoma rebounding and dry eye revenue declining as expected. Gross margins remained strong, cash usage improved, and guidance was narrowed, with double-digit glaucoma growth expected in H2 2024.